Biologics Contract Research Organization Market

Biologics Contract Research Organization Market Overview

The global biologics contract research organization market size, valued at USD 27.0 billion in 2024, is projected to reach USD 36.0 billion in 2025 and USD 126.0 billion by 2035, representing a CAGR of 13% during the forecast period.

To learn more about this report, request a free sample copy

Biologics Contract Research Organization Industry: In Summary

• Biologics contract research organization (CROs) is growing rapidly, driven by the rising shift towards third party services for clinical drug discovery and research.
• Big pharmaceutical players are currently outsourcing around 45% of their internal research and development (R&D) operations to CROs to meet stringent regulatory guidelines and conduct clinical research.
• North America is dominating the biologics contract research organization industry by holding 50% of the market share. This highest share is due to the increasing research on advanced targeted therapies to treat patients with chronic conditions, such as cancer, and autoimmune diseases.
• In terms of biologics, the antibody segment holds the largest share due to the high demand for antibodies to treat infectious diseases, such as cancer, and other chronic conditions.
• Partnerships and collaborations for technological advancements and platform expansion to support drug research are likely to strengthen the biologics contract research organization market growth.
• Notable trends that are shaping future market growth includes decentralized and virtual clinical trials that helps to conduct clinical trials virtually without engaging patients to trial location.

Biologics contract research organization industry is witnessing an upward trajectory driven by the increasing research on advanced drugs and diseases. It is evident that biologics research and development is tedious, pharmaceutical companies require extensive technological expertise, and skilled personnel which enhance overall cost of drugs. Additionally, stringent regulatory guidelines and approval process may delay commercialization of drugs, thereby creating a drug supply gap in the market.

In order to streamline these complex processes and overcome associated challenges, major pharmaceutical players are increasingly outsourcing their biologics research and development activities to specialized contract research organizations (CROs). This strategic outsourcing allows them to leverage external expertise, accelerate drug discovery and clinical trials, and ultimately bring innovative biologics to market more efficiently.

Interestingly, this tremendous shift towards contract research organizations has been supported by the rising focus on biologics to treat diseases. Biologics drugs offer high target specificity and can be tailored to meet unmet medical needs, which is expected to drive its demand for treating diseases.

In fact, it is estimated that big pharma players presently outsource close to 45% of their internal R&D operations to CROs. Furthermore, several pharmaceutical players, such as AbbVie (US), and Novartis (Switzerland) are increasingly engaging with third party research organizations, such as Parexel (North Carolina), Syneos Health (US), and ICON (Ireland), to reduce the strain on their internal R&D infrastructure. The contract research services segment is considered to be an indispensable part of the overall biopharmaceutical market.

Driven by the growing preferences for outsourcing, several industrial players are undertaking active initiatives. For instance, in March 2025, BioCity Biopharmaceuticals (China) and MSD (Merck Sharp & Dohme) (US) entered into a clinical trial agreement to conduct phase I / II clinical studies for evaluating BC3195 in combination with the Keytruda® (pembrolizumab). This clinical trial will focus on exploring treatment for patients suffering from metastatic solid tumors. As more companies continue to forge outsourcing agreements, we anticipate that biologics contract research organization market will grow steadily in the upcoming years.

Biologics Contract Research Organization Market: Report Attributes

Key Report Attributes	Details
Historical Trend	Since 2020
Forecast Period	Till 2035
Market Size 2025	USD 36.0 Billion
Market Size 2035	USD 126.0 Billion
CAGR (Till 2035)	13%

One of the key objectives of the biologics contract research organization market report was to estimate the current size, opportunity, and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.

The global biologics contract research organization market analysis report also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of biologics, scale of operation end user, geographical regions, and leading players.

In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.

What are the Recent Developments in Biologics Contract Research Organization Market?

Several recent developments in the field of biologics contract research industry have occurred, and we outlined some of these below.

• In May 2026, GI Partners acquired Charles River Laboratories and created a new company called Rose BioSolutions. This new company offers complete manufacturing services for biologics and advanced therapies, including plasmid DNA, viral vectors, and cell therapy support.
• In March 2026, Cipla and Kemwell Biopharma formed a joint venture in order to develop and manufacture biologics and biosimilars. The partners plan an initial investment of about INR 10 crore and aim to strengthen global biologics capabilities, indirectly increasing demand for CRO and CDMO services supporting development and commercialization.
• In February 2026, ORF Biologics and Vipragen Biosciences announced a strategic alliance, combining recombinant protein expertise with CRO preclinical capabilities. The collaboration focuses on biologics assay development, immunogenicity testing, and biomarker identification, aiming to accelerate drug discovery workflows and provide integrated CRO services for biologics and biosimilars research globally.
• In January 2026, Zydus Lifesciences announced the acquisition of Agenus’s biologics manufacturing facilities establishing Zylidac Bio in the US. The move strengthens Zydus’ presence in the global biologics CDMO sector, enabling expanded contract development and manufacturing services and enhancing its positioning within outsourced biologics research and production markets.

Biologics Contract Research Organization Market Segmentation Insights

The market report provides comprehensive information on biologics contract research services providers who are currently active across various segments of the industry as mentioned in the table below.

Biologics Contract Research Organization Market: Market Segmentation

Market Segmentation	Details
Type of Biologics	Vaccines Cell Therapy Gene Therapy Antibodies Recombinant Proteins / Peptides Others
Scale of Operation	Discovery Preclinical Clinical
Therapeutic Area	Oncological Disorders Cardiovascular Disorders Inflammatory Disorders Neurological Disorders Other Therapeutic Areas
End User	Small Companies Mid-Sized Companies Very Large / Large Companies
Geographical Regions	North America Europe Asia-Pacific Middle East and North Africa Latin America

How is Biologics Contract Research Organization Market Segmented?

Market Share by Type of Biologic: Antibodies Holds the Largest Share

• This segment is distributed across different type of biologics, such as vaccines, cell therapy, gene therapy, antibodies, recombinant proteins / peptides, and others. According to the biologics contract research organization market report, presently the antibodies segment holds the highest share (45%), and the trend is likely to remain unchanged. This is primarily due to the rising demand for antibodies to treat a wide range of disease indications, specifically infectious diseases.
• It is worth noting that cell therapy segment is likely to grow at a higher CAGR during the forecast period. This can be attributed to the rising shift towards targeted therapies to treat chronic conditions.

Market Share by Scale of Operation: Clinical Segment Dominating the Market

• Based on scale of operation, the global market is segmented into discovery, clinical and preclinical. Among these, the clinical segment holds the largest biologics contract research organization market share (86%). This can be attributed to the growing focus on accelerating clinical trial for faster drug approval.
• It is worth mentioning that pharmaceuticals and biotechnology companies are leveraging contract research organizations for regulatory compliance and streamline clinical operations. Therefore, the clinical segment is likely to remain dominant and is poised to grow at a higher CAGR during the forecast period.

Market Share by Therapeutic Area: Oncological Disorders Occupy the Highest Share

• Based on the therapeutic area, the global market is segmented into oncological disorders, cardiovascular disorders, inflammatory disorders, neurological disorders, and other therapeutic areas. According to biologics contract research organization market forecast, currently oncological disorders segment holds the largest share (39%) of the market. This can be attributed to the increasing research on oncological disorders and continuous emphasis on the development of targeted therapies to treat cancer patients.
• Notably, in the future neurological disorders segment is anticipated to register a higher CAGR during the forecast period. This is primarily due to the increasing demand for advanced therapeutics to treat patients with neurological conditions, such as Alzheimer’s and Parkinson’s disease.

Market Share by End User: Small Segment Holds the Largest Share

• The end user segment is divided into small companies, mid-sized companies and very large / large companies. Currently, small companies segment holds the largest share (68.2%) of the biologics contract research organization market size. This can be attributed to the fact that small companies are likely to outsource biologics research and development to reduce overall cost of therapeutic drugs.
• It is important to highlight here that small companies segment continue to dominate, anticipated registering higher CAGR during the forecast period. Small companies continue to leverage outsourcing services for clinical operations to streamline their research, development and approval process. Hence, this segment will continue to grow steadily in the upcoming years.

Market Share by Geographical Regions: North America Holds the Maximum Share

• The global market is distributed across different regions, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Currently, North America accounts for the largest share (50%) of the biologics contract research organization market. This can be attributed to the rising research for advanced drugs and expanding pharmaceutical companies that are greatly focused on the identification of new treatments to meet unmet medical needs.
• The market in Asia-Pacific is likely to witness substantial growth, anticipated to register higher CAGR during the forecast period. This is largely due to the improve regulatory framework for clinical trials, availability of large patient volunteers to recruit for clinical trials and growing demand for biologics that drives the research on advanced drugs.

Biologics Contract Research Organization Market: Report Deliverables

Report Deliverables	Details
Excel Data Packs (Complimentary)	Available
Key Biologics Contract Research Organization Profiled	Biocon (India) Covance (US) ICON (Ireland) Medpace (US) Pharmaron (China) PPD (US) PRA Health Sciences (US) Syneos Health (US) Vimta Labs (India) WuXi AppTec (China) (A complete list of companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization

What are the Biologics Contract Research Organization Market Major Takeaways?

The “Biologics Contract Research Organization Market Report: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics, and future opportunities for biologics contract research organization industry players. The market research report lays emphasis on the biologics contract research organization services that are being offered to pharmaceutical companies. Key takeaways of the market report are briefly discussed below.

How is Biologics Contract Research Organization Market Competitive Landscape Fragmented?

The current market landscape of biologics contract research organization is highly competitive, featuring a wide array of well-established and new entrants. It is worth noting that more than 160 companies are currently engaged in the biologics contract research organization market offering research services for various biotherapeutics. These CROs are greatly emphasis on collaborations and partnerships to strengthen the development of biologics.

Interestingly, several partnership deals have been inked between the stakeholders engaged in biologics contract research organization market, highlighting the consolidation efforts of the players in this industry.

For instance, in March 2025, Mural Health Technologies (US) and ICON (Ireland) announced a strategic partnership to utilize participant management and payment platform. Under this partnership ICON (US) will leverage Mural Link’s functionality related to site-participant communication tools, travel and concierge support, tax management, clinical trial participant payments, novel reporting and analytics capabilities.

Furthermore, in June 2025, Lotte Biologics (South Korea) signed a tri-party memorandum of understanding with Excelled (US) and Kanaph Therapeutics (South Korea). Under this agreement, these companies will collaborate on the joint research and development of next-generation anticancer drug ADC development, including payloads and linkers.

What are the Key Biologics Contract Research Organization Market Drivers?

Increasing Research on Cancer and Neurological Disorders

Several factors that are driving the market include growing demand for biologics and rising research on disease indications, such as cancer and neurological disorders. Additionally, the growing focus on personalized medicine to meet individual patient characteristics and genetic profiles serves as another significant driver for the market. As the biologics pipeline continues to expand, pharmaceutical and biotechnology companies are increasingly outsourcing specialized services required for biologic drug development to CROs, enabling them to manage high costs, complexity, and time constraints more effectively.

What are the Significant Challenges in Biologics Contract Research Organization Industry?

High Cost Associated with Biologics Contract Research Organization for Monoclonal Antibody Development

Despite the lucrative growth, the biologics CRO market faces several significant challenges that could impact market growth in the upcoming years. Notably, high cost and complexity of monoclonal antibody / biologic drugs development represent primary constraints, as biologics require specialized expertise, advanced technologies, and significant infrastructure investment.

Complex Regulatory Guidelines

These factors can create challenges specifically for smaller CROs seeking to establish competitive positions in the market, potentially limiting the diversity of service providers available to pharmaceutical companies. Furthermore, the complex regulatory requirements for biologic drugs, including rigorous clinical trial protocols and stringent research standards, can delay development timelines and increase costs substantially.

What are the Emerging Biologics Contract Research Organizations Market Trends?

Rise in Biosimilars to Treat Diseases

The market for biologics contract research organization is witnessing several transformative trends that are reshaping the industry. Some of the noticeable trends include the rise of biosimilars, which presents significant opportunities for CROs to support the development and regulatory approval of cost-effective biologic alternatives. As patent protections expire for many established biologic therapies, the biosimilar market is expected to expand substantially, creating demand for specialized development and regulatory support services.

Furthermore, adoption of artificial intelligence for automation presents opportunities for CROs to improve efficiency, streamline clinical trials, and shorten development timelines. AI applications in biologics development include optimizing research processes, improving yield and product quality, predicting market trends, and enhancing regulatory compliance.

Adoption of Decentralized and Virtual Clinical Trials

The growth of decentralized and virtual clinical trials represents another significant trend, accelerated by the growing demand for biologics has further offered opportunities to industrial players for transforming contract research organization services. These approaches can improve patient recruitment, reduce trial costs, and enhance data quality while providing greater convenience for trial participants. CROs with capabilities in virtual trial design and execution are positioned to capture growing demand for these innovative approaches.

Biologics Contract Research Organization Market Size Analysis

The global biologics contract research organization market size is valued at USD 36 billion in 2025 and is poised to reach USD 126 billion by 2035. In terms of scale of operation, presently the clinical operations segment holds the highest share of the market. This dominance is due to the growing number of biologics entering clinical development phases, including gene therapies, monoclonal antibodies, and cell therapies. The need for specialized expertise, scalability, and cost-effectiveness in conducting these trials has solidified the clinical segment's dominance in the biologics CRO market.

Biologics Contract Research Organization Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in the biologics contract research services providing industry, across different geographies. Amongst other elements, the market report includes:

• An Infographic Executive Summary
• Market Landscape of Biologics Contract Research Organizations
• Company Profiles
• Benchmark Analysis
• Partnerships and Collaborations
• Mergers and Acquisitions
• Attractiveness Competitiveness Matrix
• Market Forecast Analysis
• Market Opportunity Analysis
• Market Distribution by Geographical Regions
• SWOT Analysis

From the Author’s Desk

Author’s View on Biologics Contract Research Organization Market

The biologics CRO market represents one of the most compelling growth opportunities within the broader pharmaceutical services industry. The convergence of increasing biologic drug complexity, expanding therapeutic applications, and growing outsourcing adoption creates a favorable environment for market expansion. However, this market requires substantial investment in specialized capabilities, advanced technologies, and expert personnel. The most significant opportunity lies in the development of integrated service platforms that combine comprehensive biologics expertise with cutting-edge technologies, such as artificial intelligence, automation, and digital health tools.

Glossary

• Biologics: It refers to therapeutic products derived from living organisms, including proteins, antibodies, vaccines, and cell and gene therapies, typically manufactured using biotechnology processes.
• Contract Research Organization (CRO): It refers to the specialized service provider that supports pharmaceutical and biotechnology companies in drug development activities, including clinical trials, regulatory affairs, and data management.
• Cell Therapy: It involves the introduction of living cells into a patient to treat or cure disease, often involving genetic modification or manipulation of the cells.
• Gene Therapy: It refers to the therapeutic drugs that involves introducing genetic material into a patient's cells to correct defective genes or provide new cellular function.
• Monoclonal Antibodies (mAbs): It refers to the engineered antibodies designed to target specific antigens, commonly used in cancer treatment and autoimmune disease management.

Frequently Asked Questions

Question 1: What is a biologics contract research organization?

Answer: A biologics contract research organization is a special kind of an organization, offering contract research services to pharmaceutical companies for various kinds of vaccines, biologics and other biopharmaceuticals.

Question 2: How big is the market for biologics contract research organization?

Answer: The biologics contract research organization market size is estimated to be worth USD 36.0 billion in 2025.

Question 3: What is the projected market growth of the biologics contract research organization?

Answer: The biologics contract research organization market is expected to grow at a compound annual growth rate (CAGR) of 13% during the forecast period.

Question 4: Who are the leading companies in the biologics contract research organization industry?

Answer: Examples of key companies engaged in biologics contract research organization market include Biocon (India), Covance (US), ICON (Ireland), Medpace (US), Pharmaron (China), PPD (US), PRA Health Sciences (US), Syneos Health (US), Vimta Labs (India) and WuXi AppTec (China).

Question 5: What is the difference between CDMO and CRO?

Answer: A contract development and research organization (CDMO) generally involves in the development and research of therapeutic drugs. In contrast, a contract research organization (CDRO) specializes in research and clinical trials and supports drug discovery and regulatory approval.